Latest Conference Articles

In a recent interview, Timothy Fairbairn, Ph.D., and Fatima Rodiguez, M.D., discussed new research findings, recently presented at the American Heart Association (AHA) conference, showing the value of AI-powered quantification of plaque burden from CCTA exams for predicting adverse cardiovascular outcomes.

In a recent interview, Hari Kishan Gonuguntla, M.D., discussed AI-powered evaluation of chest X-rays with the Lung Nodule Malignancy Score software and key findings from multinational prospective research presented at the recent ESMO Congress 2025 meeting.

Use of the radiotherapeutic agent 177Lu-edotreotide (ITM-11) demonstrated significantly higher absorption in gastroenteropancreatic neuroendocrine tumors than normal organs along with a favorable safety profile, according to SPECT research recently presented at the European Association of Nuclear Medicine (EANM) conference.

Pluvicto in combination with the standard of care led to a 28 percent reduction in the risk of radiographic progression or death in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to results from the phase III PSMAddition trial presented at the European Society for Medical Oncology (ESMO) conference.

For patients with relapsing multiple sclerosis, switching from oral therapies to subcutaneous monthly administration of the anti-CD20 monoclonal antibody ofatumumab led to over a 98 percent reduction of Gd+ T1 lesions on MRI at 96 weeks.

Facilitating increased efficiency in radiation therapy planning, the new Rembra RT and Areta RT computed tomography platforms reportedly offer 4D CT capabilities and image reconstruction speeds up to 106 images per second.

Emphasizing enhanced connectivity, the latest version of the Intelligent Radiation Therapy (iRT) software may facilitate improved workflow efficiencies with the planning, performance and reporting for radiation therapy.

The AI-powered cardiovascular ultrasound device reportedly offers enhanced spatial and contrast resolution as well as bolstered 4D imaging that enables improved evaluation of cardiac function for a wide range of patients.

Combining advances in imaging quality with access to 26 FDA-cleared applications for automated and accelerated tasks, the Transcend Plus software will be featured at the upcoming European Society of Cardiology (ESC) and American Society of Echocardiography (ASE) conferences.

The dose length product (DLP) for the flash mode on a dual-source photon-counting CT system was less than a third of that for the spiral mode, according to a study of CTA findings for 1,000 patients presented at the Society of Cardiovascular Computed Tomography (SCCT) conference.

In a recent interview, Amir Ahmadi, M.D., discussed limitations of conventional diagnostic assessments for people with suspected coronary artery disease, and the emergence of AI-enabled plaque quantification to facilitate more timely detection and intervention.

Catch up on recent interviews with Jean-Luc C. Urbain, M.D., Amir Iravani, M.D., Liza Lindenberg, M.D., and more faculty from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 conference.

In a recent interview at the SNMMI conference, Ryota Satoh, Ph.D., discussed new positron emission tomography (PET research examining the role of neuroinflammation in differentiating between progressive apraxia of speech (PAOS) and Parkinson-plus syndrome.

In a recent interview, Jean-Luc C. Urbain, M.D., Ph.D., the new president of the Society for Nuclear Medicine and Molecular Imaging, discussed current challenges in nuclear medicine and key goals, including improved access to nuclear medicine for people in underserved communities.

In a recent interview at the SNMMI conference Amir Iravani, M.D., discussed a new sub-analysis from the CONDOR study, which revealed consistently high positive predictive value for 18F-piflufolastat PSMA PET/CT in the detection of local prostate cancer recurrence.

In a recent interview at the SNMMI conference, Liza Lindenberg, M.D., discussed preliminary research findings that suggest the potential of the 18F-fluciclovine PET/CT for detection of multiple myeloma.

For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.

In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.

In a recent interview at SNMMI conference, Merle Hoenig, Ph.D., discussed new tau PET research examining genetic and modifiable risk factors that contribute to the progression of Alzheimer’s disease.

In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.

The dual-targeted 177Lu-DOTA-FAPI-RGD reportedly reduced or stopped the growth of cancer lesions in 88.9 percent of advanced adenocarcinomas in a small cohort of patients with varied cancers including pulmonary, pancreatic and ovarian cancer, according to new research presented at the SNMMI conference.

While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.

Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.

Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.

A partial response rate to neoadjuvant chemotherapy on mid-treatment MRI preceded a higher pathologic complete response (pCR) in 61.5 percent of women with triple-negative breast cancer, according to research presented at the American Society of Clinical Oncology (ASCO) conference.

High allostatic load, which has been linked to an increased incidence of breast cancer and all-cause mortality, is more than twice as likely to occur in Black and Hispanic women in comparison to White women, according to mammography research presented at the American Society of Clinical Oncology (ASCO) conference.

Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.

The Rapid CTP AI software offered 23 percent greater detection of medium vessel occlusions in comparison to the Viz CTP AI software, according to research presented at the European Stroke (Organization) Conference (ESOC).